Rallybio/RLYB

$1.97

-16.52%
-
1D1W1MYTD1YMAX

About Rallybio

Rallybio Corporation is a clinical-stage biotechnology company. The Company is engaged in identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. It offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease that impacts fetuses and newborns. Its pipeline includes RLYB212, RLYB116, RLYB114, RLYB331 and ENPP1 Program. RLYB212 is a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for the prevention of HPA-1a maternal alloimmunization and the occurrence of FNAIT. Its advanced product candidate, RLYB116, is an inhibitor of complement component 5 (C5) used to treat complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG) and others. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule designed for the treatment of complement-mediated ophthalmic diseases.

Ticker

RLYB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Martin Mackay

Employees

44

Headquarters

New haven, United States

Rallybio Metrics

BasicAdvanced
$89.19M
Market cap
-
P/E ratio
-$1.80
EPS
-
Beta
-
Dividend rate

What the Analysts think about Rallybio

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 6 analysts.
572.59% upside
High $30.00
Low $1.50
$1.97
Current price
$13.25
Average price target

Rallybio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-18.3M
-1.61%
Profit margin
0%
-

Rallybio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.52%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.46
-$0.43
-$0.46
-$0.45
-
Expected
-$0.60
-$0.49
-$0.48
-$0.51
-$0.46
Surprise
-22.82%
-11.47%
-3.74%
-11.52%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Rallybio stock

Buy or sell Rallybio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing